Drug Profile
Research programme: HIV integrase inhibitors - Amgen
Alternative Names: HIV integrase inhibitors research programme - AmgenLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Tularik
- Class
- Mechanism of Action HIV integrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 09 Dec 2003 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)
- 12 Jul 2001 Preclinical development for HIV infections treatment in USA (Unknown route)
- 21 Oct 1999 Proteus International has merged with Therapeutic Antibodies to form Protherics